
COVID-19 Vaccine human clinical trials: Immune response evaluation in various populations



(IIV-Clb/RIVM)



FFX/RIVM

Academia

Kidney disease and/or transplantation: RECOVAC

- Lung disease and/or transplantation: COVALENT

i - Down syndrome: PRIDE

Harmonized timepoints

- 1. Before vaccination
- 2. 4 Weeks after 1st vaccination
- 3. 4 Weeks after 2nd vaccination
- 4. 6 Months after 2nd vaccination
- 5. 12 Months after 2nd vaccination

Harmonized measuring of antibodies

- High throughput bead-based multiplex immune assay (MIA)
- Antibody (IgG) 28 days after 2nd vaccination as primary parameter

Integrated approach

Majority of studies include a spectrum of immune responses:

- T-cells
- B-cells
- Innate cells
- Serology

Questionnaires on COVID-19

PICO/RIVM !

- Local immunity (e.g. antibodies in the nose)
- Role of gut microbiome